Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.64 |
| ▸ | RXRB | P28702 | 3/20 | 0.64 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.61 |
| ▸ | CTRC | Q99895 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.54 |
| ▸ | TPMT | P51580 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
| ▸ | DHODH | Q02127 | 2/20 | 0.53 |
| ▸ | ALAD | P13716 | 1/20 | 0.52 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | CDH1 | P12830 | 1/20 | 0.50 |
| ▸ | APC | P25054 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8628997 | 0.87 | TPMT (0.74) | RXRARXRBNOTUMCTRCALOX15 | |
| SCHEMBL2723882 | 0.87 | RXRA (0.55) | RXRARXRBNOTUMCTRCALOX15 | |
| SCHEMBL29727618 | 0.87 | RXRA (0.55) | RXRARXRBNOTUMCTRCALOX15 | |
| SCHEMBL18496631 | 0.87 | RXRA (0.55) | RXRARXRBNOTUMCTRCALOX15 | |
| SCHEMBL18604547 | 0.86 | DHODH (0.67) | RXRARXRBDHODHKMOEGFR | |
| SCHEMBL4246903 | 0.86 | DHODH (0.67) | RXRARXRBDHODHKMOEGFR | |
| SCHEMBL2041424 | 0.84 | TSHR (0.85) | RXRARXRBCTRCALOX15TSHR | |
| SCHEMBL15120764 | 0.84 | EGFR (0.67) | RXRARXRBTSHRSRD5A2DHODH | |
| SCHEMBL15814719 | 0.84 | DHODH (0.69) | RXRARXRBAURKATPX2DHODH | |
| SCHEMBL16488615 | 0.84 | DHODH (0.69) | RXRARXRBAURKATPX2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2016039-B1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO MCNEIL JANSSEN PHARM (US) | 2012-08-01 | — | — | EP | claimed |
| US-8106236-B2 | Triaryl compounds and derivates thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-01-31 | — | — | US | claimed |
| EP-1847524-B1 | Terphenyl derivatives for treatment of Alzheimer's disease | CELLZOME LTD (GB) | 2009-10-14 | — | — | EP | claimed |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-11-01 | — | — | US | claimed |
| EP-1847524-A1 | Terphenyl derivatives for treatment of Alzheimer's disease | Cellzome (UK) Ltd. (GB) | 2007-10-24 | — | — | EP | claimed |
| EP-2016039-B1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO MCNEIL JANSSEN PHARM (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8106236-B2 | Triaryl compounds and derivates thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1847524-B1 | Terphenyl derivatives for treatment of Alzheimer's disease | CELLZOME LTD (GB) | 2009-10-14 | — | — | EP | disclosed |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1847524-A1 | Terphenyl derivatives for treatment of Alzheimer's disease | Cellzome (UK) Ltd. (GB) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | BACE1, BACE2, APP | RXRA 1179/4885RXRB 1173/4885NOTUM 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.